Healthcare Cost Surge: Unprecedented Spike in Employer Healthcare Spending Anticipated
The climbing rates of healthcare inflation are pushing coverage expenses higher, pointing towards a potentially historic rise in healthcare expenditures by major employers, marking a record not seen in the past fifteen years.
Data from the Labor Department reveals that in August, the annual growth in medical care expenses reached 4.2%, surpassing the general inflation rate of 2.9%. Charges for physician services saw a 3.5% hike, and expenses for hospital and outpatient care shot up by 5.3%.
These rising costs are setting the stage for increased health insurance premiums in 2026. Customers purchasing coverage through the Affordable Care Act exchanges without government support might encounter significant premium hikes for the upcoming year, based on preliminary insurer filings.
Employees participating in employer-sponsored health plans may also see a rise in both insurance premiums and out-of-pocket expenses.
Surveys from various business groups indicate that big employers expect their overall healthcare costs to increase on average by 9% in 2026, marking the most substantial healthcare inflation rate since a decade ago.
Over half of companies surveyed earlier by a benefits consulting firm are contemplating transferring part of these increased costs to employees; however, the Business Group on Health reports that most large employers are actively seeking alternative cost-cutting measures.
Key Cost Factors: Cancer Drugs and GLP-1s
In August, prescription medication prices experienced a 0.9% rise, as indicated by the Consumer Price Index, examining a spectrum of common generic and branded medications.
Significant cost spikes for employers arise from high-priced drugs. The Business Group on Health anticipates a 12% hike in pharmaceutical expenses next year, following an 11% rise this year largely due to cancer therapies and weight management medications, like Wegovy and Zepbound.
For the fourth consecutive year, cancer remains the top condition inflating healthcare costs, with earlier onset and advanced stage diagnoses adding to the burden, followed by expensive weight-loss drugs.
The focus on obesity treatments has intensified in recent years, further driving pharmacy expenses in this area.
According to Mercer, nearly two-thirds of companies with 20,000 or more employees offer GLP-1 weight-loss drugs, whereas under half of smaller businesses plan to offer them by 2026.
As the appetite for these medications grows, companies are exploring stricter eligibility criteria and more economical provision options, such as engaging with the cash-pay sector.
Adoption of Cash-Pay GLP-1 Options
A leader from a telehealth company stated that some large companies are discreetly informing their employees about using health savings accounts to purchase medications more affordably through the cash market.
There is concern over the costs, yet these companies do not wish to deny employees access, preferring not to shoulder the full expense.
Reports from health accounts reveal an increasing trend among employees opting for direct consumer models, such as services offered by Eli Lilly and Novo Nordisk's online platforms, which provide weight-loss drugs at approximately half the typical price of over $1000.
Presently, GLP-1 medication purchases are the leading category for cash-pay spending through pre-taxed health savings and flexible spending accounts for non-insurance covered expenses, as announced by the CEO of Paytient.
Health payments company Paytient's CEO, Brian Whorley, notes a threefold rise in spending at provider locations centered on GLP-1 medications.
Yet, companies are concerned about excluding lower-income employees from access due to prohibitive out-of-pocket costs, inciting dialogue on securing cash-pay rates for more equitable employee access.
While self-insured employers have set direct contracts with specialized care facilities for complex treatments, they currently face restrictions in doing so for many drug purchases.
However, companies are urging pharmacy benefits managers (PBMs) to offer better solutions, including emergent benefit managers suggesting novel drug payment models under development.
Health leaders like Ellen Kelsay from BGH express that young firms are devising innovative strategies to negotiate with drug manufacturers on behalf of a collective of employers.
Brian Whorley from Paytient describes efforts to ensure affordable GLP-1 access as a decisive challenge for companies and PBMs, crucial for setting a precedent for handling high-impact drugs.



Leave a Reply